September 13, 2005 -- The FDA gave Pfizer and Ligand a thumbs down on their osteoporosis drug, Oporia, a drug that once showed a great deal of promise, plus Ligand disclosed an SEC probe of its financial reports restatement, Novagen will spin off its US subsidiary Glycotex in an IPO, Novagen also reported positive data from its cardiovascular drug, the FDA lifted its clinical hold on a Phase I test of a rheumatoid arthritis drug from Protalex, and Angiotech bought a company involved, like Angiotech, in wrapping arteries. Meanwhile, the Centient Biotech 200 continued its consolidation, moving 28 points lower to end at 3890.06, a loss of .73%. More details...
